Lumida
/CYTK
⌘K
Cytokinetics Inc

Cytokinetics Inc

CYTK
$80.18USD↓-0.22%-0.18 today

MARKET CAP

10.0B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$78 – $83

52W RANGE

$33
$88

AI Summary

Stalk
Sell NowMedium

CYTK's Stage 2 uptrend has entered a terminal Blow-Off Top phase marked by extreme overbought readings and high Stage 213 transition risk. The active Blow-Off Top pattern and rejection at recent highs indicate unsustainable buying pressure and initial pullback, warranting a Sell Now into the spike high/resistance zone.

  • ↑Q1 myCORSO net product revenue reached $4.8M in nine weeks
  • ↑Total revenues jumped to $19.4M from $1.6M YoY on launch momentum
  • ↓Q1 net loss totaled $206M, raising burn‐rate concerns
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Cytokinetics, Inc. (NASDAQ: CYTK) is an innovative biopharmaceutical company primarily focused on developing cutting-edge therapies targeting hypertrophic cardiomyopathy (HCM). With a strategic emphasis on muscle-targeted treatments, Cytokinetics is making significant strides towards commercialization, especially following the recent approval and market entry of myCORSO, a novel cardiac myosin inhibitor. The company operates within the emerging landscape of specialty biopharma, where addressing unmet medical needs related to heart conditions presents substantial growth opportunities.

Bull says

  • ↑Q1 myCORSO net product revenue reached $4.8M in nine weeks
  • ↑Total revenues jumped to $19.4M from $1.6M YoY on launch momentum
  • ↑Acacia HCM trial met dual endpoints, boosting aficamten’s market case
  • ↑Cash position of ~$1.1B funds R&D and commercial expansion
  • ↑Plan to launch myCORSO in Germany covering ~90% of Medicare lives
  • ↑Strong momentum factors and positive analyst revisions support outlook

Bear says

  • ↓Q1 net loss totaled $206M, raising burn‐rate concerns
  • ↓Weak profitability factors persist with negative earnings yield
  • ↓PDUFA date extended to Dec 26, 2025, postponing aficamten launch
  • ↓Cash and equivalents fell by ~$132M in Q1, stressing liquidity
  • ↓Competition from established therapies may hinder uptake momentum
  • ↓Negative valuation and balance‐sheet vulnerabilities heighten risk

Investment themes with CYTK

Biotech↓ -3.20%

Genetic and drug innovations driving medical breakthroughs

APLS · RVMD · SMMT

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-09-2026bullish

Transcript signals

Bull points

  • This morning, we were thrilled to report the top-line results from Acacia HCM. The trial met both of its dual primary endpoints, demonstrating statistically significant improvements from baseline to week 36 in both KCCQ clinical summary score and peak VO2 compared to placebo.
  • Importantly, there were no new safety signals identified. Percentage of patients who completed treatment in Acacia HCM was similar between those receiving apicamtin or a placebo.
  • The improvement in KCCQ was robust and consistent throughout the treatment period.

Bear points

  • Net loss for the first quarter of 2026 was $206 million, or $1.67 per share, compared to a net loss of $161.4 million, or $1.36 per share, for the same period in 2025.
  • Cash and investments declined by approximately $144 million during the first quarter of 2026.
Read full transcript analysis ›